SMURF2 and cancer: Our studies have shown that when ER was no/mild, 61.29 and 58.06% of malignant tumors showed moderate/intense expression of Smurf2 and CNKSR2, while only 29.03% of malignant tumors showed moderate/intense expression of Smurf2 and CNKSR2 when ER was moderate/intense.